Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: R-(-)-gossypol acetic acid, cisplatin, etoposide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Sioux Falls, South Dakota • La Crosse, Wisconsin • Madison, Wisconsin

Conditions: Osteochondritis Dissecans
Interventions: Other: observational only- no intervention; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2074
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: TT-00920, Placebos; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 27 more

Conditions: Cataract, Cataract Senile, Presbyopia
Interventions: Vivity Extended Depth of Focus Intraocular Lens; Device
Lead sponsor: Alanna Nattis, DO; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Babylon, New York

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Long QT Syndrome
Interventions: LQT-1213, Placebo; Drug · Other
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions: Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI; Other · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Cloud-based Digital Twin and Meal Prediction algorithms; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Loma Linda, California • Walnut Creek, California • Aurora, Colorado + 8 more

Conditions: Cutaneous Melanoma, Synovial Sarcoma
Interventions: IMA203, mRNA-4203; Biological
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Advanced Cancer
Interventions: BMS-986258, Nivolumab, rHuPH20; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Sinusitis, Nasal Polyps
Interventions: Verapamil Hydrochloride Intranasal; Drug
Lead sponsor: Benjamin Bleier; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Lung Cancer, Head and Neck Cancer
Interventions: cetuximab and lapatinib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Solid Tumors
Interventions: Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced or Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 11
States / cities: Tampa, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Opioid Use Disorder
Interventions: Tezampanel, Placebo; Drug
Lead sponsor: Proniras Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Volunteers
Interventions: NUV001 active cohort 1, NUV001 active cohort 2, NUV001 active cohort 3, NUV001 active cohort 4, NUV001 placebo cohort 1, NUV001 placebo cohort 2, NUV001 placebo cohort 3, NUV001 placebo cohort 4; Drug
Lead sponsor: Nuvamid SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lymphoma
Interventions: CAT-8015; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Beverly Hills, California • Bethesda, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more

Conditions: Infertility, Cardiovascular Risk Factor
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 55 Years · Female only
Enrollment: 865 participants
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Tafasitamab, Lenalidomide; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Morristown, New Jersey • Dallas, Texas • Olympia, Washington

Conditions: West Nile Virus
Interventions: MGAWN1, Placebo; Drug · Other
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Interventions: Obrixtamig, Pumitamig, Carboplatin, Etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more

Search by objective public record fields.

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Osteochondritis Dissecans of Knee Prospective Cohort

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Phase 1 Study of LQT-1213 in Healthy Adults

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Feasibility Studies of Personalized Closed Loop

ACTengine® IMA203 Combined With mRNA-4203

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

Lapatinib and Cetuximab in Patients With Solid Tumors

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The Longitudinal Evaluation of Ovarian Aging and Cardiovascular Risk

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)